GICS Sector : Healthcare
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States.It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury.The company was incorporated in 2016 and is based in Los Altos, California. Show Full description
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf
Feb -17
Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech Summit
Feb -04
Unicycive: 'Buy' Rating On NDA Resubmission OLC And Potential Best-In-Class Profile
Jan -29
UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
Jan -29
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
Jan -29
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)
Dec -29
Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf
Dec -01
Unicycive Therapeutics to Participate in Upcoming Investor Events in December
Nov -25
Unicycive Therapeutics' novel therapies drive 9.27% growth, fueled by increasing demand for innovative treatments, strategic partnerships, and expanding pipeline of rare disease therapies. Strong R&D investments, favorable regulatory environments, and growing awareness of rare genetic disorders also contribute to this growth.
A novel, orally bioavailable, small molecule inhibitor of soluble epoxide hydrolase (sEH) for the treatment of various inflammatory diseases
A novel, orally bioavailable, small molecule inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH) for the treatment of autoimmune diseases
A novel, orally bioavailable, small molecule inhibitor of the enzyme indoleamine 2,3-dioxygenase (IDO) for the treatment of cancer
Unicycive Therapeutics, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies in the market.
Unicycive Therapeutics, Inc. has a low bargaining power of customers due to the lack of concentration of buyers in the market.
Unicycive Therapeutics, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers in the market.
Unicycive Therapeutics, Inc. has a high threat of new entrants due to the attractiveness of the market and the ease of entry.
Unicycive Therapeutics, Inc. operates in a highly competitive market with many established players, leading to a high intensity of rivalry.
| Value | |
|---|---|
| Debt Weight | -27.05% |
| Debt Cost | 10.11% |
| Equity Weight | 127.05% |
| Equity Cost | 17.40% |
| WACC | 19.37% |
| Leverage | -21.29% |
Value: 8.6
Growth: 6.1
Quality: 6.2
Yield: 0.0
Momentum: 6.0
Volatility: 3.7
1-Year Total Return ->
Value: 10.0
Growth: 7.0
Quality: 6.2
Yield: 0.0
Momentum: 6.0
Volatility: 0.0
1-Year Total Return ->
Value: 8.4
Growth: 4.2
Quality: 3.4
Yield: 0.0
Momentum: 8.5
Volatility: 0.3
1-Year Total Return ->
Value: 0.7
Growth: 7.9
Quality: 5.9
Yield: 0.0
Momentum: 2.0
Volatility: 3.7
1-Year Total Return ->
Value: 6.7
Growth: 4.8
Quality: 3.8
Yield: 0.0
Momentum: 3.5
Volatility: 1.3
1-Year Total Return ->
Value: 6.7
Growth: 0.3
Quality: 3.2
Yield: 0.0
Momentum: 0.5
Volatility: 1.3
1-Year Total Return ->